Clinical Trials Browser

Not yet recruiting × Carcinoma, Renal Cell × Specimen Handling × Clear all

NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07578025 2026-05-11

Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Phase 2 Not yet recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT07037004 2026-05-04

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Phase 3 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07226544 2025-11-10

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07218692 2025-10-20

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell